The biotech space is the one sector where early-stage winners are difficult to find because of the complexity of the medical breakthroughs that young life-science companies are trying to achieve.
Similarly in business, if a senior biopharma executive was forced every day to step through even of fraction of the actual complexity of the science associated with every product, it would be overwhelming, and make decision-making all but impossible.